○ASCO Report―2015 ASCO Annual Meeting
1.Retrospective analysis of CA19-9 decrease in patients
with metastatic pancreatic carcinoma(MPC) treated
with FOLFIRINOX or gemcitabine(gem) in a randomized
phase III study(ACCORD11/PRODIGE4).
2.Randomized phase II/III trial of neoadjuvant
chemotherapy with gemcitabine and S-1 versus
surgery-first for resectable pancreatic cancer.